Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
about
Cost-Utility Analysis of Lipegfilgrastim Compared to Pegfilgrastim for the Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Stage II-IV Breast Cancer
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Cost-Utility Analysis of Lipeg ...... with Stage II-IV Breast Cancer
@en
type
label
Cost-Utility Analysis of Lipeg ...... with Stage II-IV Breast Cancer
@en
prefLabel
Cost-Utility Analysis of Lipeg ...... with Stage II-IV Breast Cancer
@en
P2093
P2860
P356
P1476
Cost-Utility Analysis of Lipeg ...... with Stage II-IV Breast Cancer
@en
P2093
Edith Maes
Esse I H Akpo
Irshaad R Jansen
P2860
P356
10.3389/FPHAR.2017.00614
P577
2017-09-13T00:00:00Z